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Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
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Conclusions. Nucleoside reverse-transcriptase inhibitor/nonnucleoside reverse-transcriptase inhibitor-based treatment regimens are highly effective in clearing rapidly replicating (phase I) virus in African patients dually infected with HIV-1 and either TB or KS.
One of the most dramatic changes in the global AIDS epidemic has been the rapid emergence and devastating spread of HIV-1 subtype C [1] [2] [3] [4] . At the end of 2001, South Africa had an estimated 4.7 million people living with HIV-1/AIDS [5] . By the year 2005, an estimated 250,000 South Africans will have died of AIDS [6] .
Young women 20-24 years of age have the highest HIV-1 incidence and prevalence rates [7, 8] .
Since we are on the brink of introducing a treatment strategy for South Africa, it is urgent that we collect information on the therapeutic response of subtype C viruses. Although it is generally accepted that drugs developed against HIV-1 subtype B will be safe and effective, the efficacy of antiretroviral therapy (ART) for the treatment of HIV-1 subtype C in Africa is largely unproven. In vitro evidence suggests that subtypes B and C are equally susceptible to antiretroviral drugs [9, 10] but that subtype C viruses have natural polymorphisms that facilitate the emergence of drug resistance [11] [12] [13] . At the patient level, studies of subtype C and of other non-B viruses have been difficult to interpret. In the Ivory Coast, treatment of patients infected with subtype A/G recombinants resulted in a 57.4% prevalence of resistance [14] . However, it is unclear whether this high level of resistance was due to the intrinsic properties of subtype A/G viruses or to poor compliance and suboptimal therapy. In contrast, studies from South Africa [15] and Senegal [16] have reported resistance rates as low as 10%-11.8%. At least 4 studies have assessed treatment outcomes in African emigrants living in Europe [17] [18] [19] [20] . In 1 study, African patients had a lower rate of CD4 + cell recovery [17] ; in a second study, African patients were found to have an earlier viral rebound, compared with that in European patients [18] . In the other 2 studies, no difference was detected in the therapeutic response of African versus non-African patients [19, 20] . All of these studies involved a small number of patients infected with a variety of different non-B HIV-1 subtypes.
The planned treatment of large numbers of patients in subSaharan Africa has underscored the urgent need to develop simple, standardized drug regimens that have a high barrier to drug resistance and that are affordable and appropriate for the treatment of non-B HIV-1. In addition to being efficacious and compatible with medications used to treat tuberculosis (TB) and other coinfections, each drug in the treatment regimen should have a prolonged half-life, so that it can be combined into a single tablet taken once daily, to reduce the risk of noncompliance. One regimen that has been successfully used to treat HIV-1 B infections in patients with active TB is a combination of didanosine (ddI), lamivudine (3TC), and efavirenz (EFV) [21] .
Here, we compare the effects of nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based triple combination ART on the dynamics of viral RNA decline and CD4 + cell restoration in South African patients dually infected with HIV-1 and either Mycobacterium tuberculosis or human herpesvirus-8 (HHV-8), the causative agent of Kaposi sarcoma (KS). The study is in keeping with international guidelines suggesting that patients with low CD4 + cell counts (!250-350 cells/mL) and patients with opportunistic infections (OIs) (regardless of their CD4 + cell counts) are likely to derive the most benefit from ART [22] [23] [24] . Statistical analyses. The short-term response to ART was assessed by measuring the median change, from baseline levels, in viral load (log 10 scale) and in CD4
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+ and CD8 + cell counts. Correlations among baseline parameters were assessed using linear regression and Spearman's correlations. Repeated-measures analysis of variance (ANOVA) was used to assess the effects of treatment and OIs on changes in these parameters over time. Statistical significance was evaluated using independent 2-tailed t tests for equality of means. Before the analyses were performed, the data were tested for normality. Estimates of the time to CD4 + cell recovery and viral load clearance were determined by Kaplan-Meier analysis. Log-rank tests were used to test equality of survival distributions between groups. All calculations were performed using SPSS software (version 11.5).
RESULTS
Demographics and baseline characteristics of the 2 patient groups. Forty-eight patients were infected with HIV-1 subtype C; 1 patient with KS was infected with subtype B. With the exception of this patient, all other patients reported heterosexual contact as the mode of HIV-1 acquisition. As shown in table 1, 24 patients were women, and 25 were men. The mean ages of the TB and KS cohorts were 31 years (range, 18-53 years) and 35 years (range, 27-49 years), respectively. There was no significant difference in the mean baseline CD4 + (206 cells/mL in the TB cohort vs. 223 cells/mL in the KS cohort) or Table 2 shows the changes in viral load and CD4 + cell counts from baseline over time. After 3 months, the mean ‫ע‬ SD decrease in HIV-1 RNA level was log 10 copies/mL Ϫ3.8 ‫ע‬ 0.8 in the TB cohort and 3 log 10 copies/mL in the KS Ϫ3.1 ‫ע‬ 0. cohort. As previously reported for HIV-1 subtype B [25] [26] [27] [28] [29] , this decrease occurred in 2 distinct phases: a rapid, nearexponential decrease, which occurred during the first 7 days of treatment (phase I), followed by a slower, more gradual phase II decline that lasted until the virus became undetectable ( figure 1A and 1B) . Although the pattern of plasma viral load ("VL" in the following equations) decay was similar in both cohorts, the depth ( ) and steeplog [VL Ϫ VL ] greater in patients with TB than in those with KS (decrease, Ϫ2.32 vs. Ϫ1.55 log 10 RNA copies/mL, respectively; slope, Ϫ0.33 vs. Ϫ0.22 log 10 RNA copies/day, respectively). The phase I decline in viral load, measured at day 7, was 99.0% in the TB cohort and 94.6% in the KS cohort. These findings indicate that, even in patients with OIs and severe disease, the vast majority of plasma virus (194%) is still being produced by actively replicating, short-lived effector CD4 + T cells [26] [27] [28] [29] [30] [31] , with the remaining virus (1.0%-5.4%) being derived a small pool of long-lived, chronically infected CD4 + CD45RO + T cells and monocyte macrophages [32] [33] [34] [35] [36] [37] [38] .
Interesting differences were observed between patients with high (1150 cells/mL) baseline CD4 + cell counts and those with low (!150 cells/mL) baseline CD4 + cell counts. Within the TB cohort, the magnitude and steepness of the phase I viral load decline was greater in the subgroup of patients with baseline CD4 + cell counts 1150 cells/mL, consistent with the view that patients with HIV-1/TB who have higher CD4
+ counts have a larger, or more active, rapidly replicating CD4 + T cell compartment. Conversely, within the KS cohort, the sharpest and most pronounced phase I viral load decline occurred in patients with baseline CD4 + cell counts !150 cells/mL. This finding may reflect the extremely low CD4 + cell counts (!10 cells/mL) observed in several of the patients with KS in our study. Patients with OIs and severe disease often have a relatively small phase I compartment, as a result of severe depletion of their CD4 + T cells [36] . CD4 + cell restoration during the first 3 months of therapy. An inverse relationship was observed between the pattern and kinetics of viral load decline and CD4 + cell restoration. The overall increase in CD4 + cell count was greater among patients with TB, compared with that among patients with KS (200 vs. 74 cells/mL). In the TB cohort, the mean CD4 + cell count increased from cells/mL at baseline to 222.6 ‫ע‬ 135.8 422.6 ‫ע‬ cells/mL at 3 months posttreatment. In the KS cohort, the 221.8 increase was from cells/mL at baseline to 280 ‫ע‬ 135.8 206 ‫ע‬ 164.9 cells/mL at month 3. The higher level of CD4 + cell restoration in the TB cohort was not unexpected, given that this group had a larger, more dynamic population of highly productive CD4 + cells. For both cohorts, the steepest increase in CD4 + cell count was observed during the first 7 days of treatment, when large amounts HIV-1 were being cleared from plasma and from the short-lived CD4 + compartment. The overall pattern of the CD4 + cell-count increase was similar in both cohorts, consisting of a transient early increase followed by a small decrease and then a second wave of increase after day 30.
Time to undetectable HIV-1 RNA in plasma. Frequency distribution estimates of the relative proportion of patients reaching undetectable virus levels (!40 copies HIV-1 RNA/mL plasma) at 7, 14, 28, 60, and 90 days were 15 x p 63.6 P ! .0001 tively, for the KS cohort. As determined by Kaplan-Meier analysis, the time required for HIV-1 clearance from mean ‫ע‬ SD the plasma of patients with TB was days, compared 62 ‫ע‬ 4 with days for patients with KS (figure 2). This difference 72 ‫ע‬ 4 was statistically significant when tested for equality of survival distribution (1 df; ). Within the TB cohort, the time P p .0333 taken to reach undetectable virus levels was significantly longer in patients with CD4 + counts !150 cells/mL ( vs. 79 ‫ע‬ 6 ‫ע75‬ days; 1 df;
). This finding is consistent with patients 4 P p .0211 with late-stage disease having a larger proportion of long-lived phase II cells [38] . Within the KS cohort, the time taken to achieve undetectable viral load levels was significantly shorter in the subgroup of patients with CD4 + cell counts !150 cells/mL ( vs. days; 1 df; ). 66 ‫ע‬ 5 ‫ע87‬ 4 P p .0572 Time required to achieve a 25% recovery of CD4 + cells. Although patients with TB had a greater overall increase in CD4 + cell counts, no statistically significant differences were observed with respect to the mean times required to achieve a 25% recovery of CD4 + cells ( days for patients with KS 42 ‫ע‬ 4 vs.
days for patients with TB; 1 df; ). When 50 ‫ע‬ 4 P p .2137 the results were stratified on the basis of mean CD4
+ cell count at entry, no difference was detected in the timing of the 25% CD4 + cell recovery in patients with TB who had low (!150 cells/mL) versus high (1150 cells/mL) baseline CD4 + cell counts ( , vs. days, respectively; 1 df; mean ‫ע‬ SD 43 ‫ע‬ 7 ‫ע35‬ 4 P p ). Within the KS cohort, the time needed to achieve a 25% .1463 restoration of CD4 + cells was significantly shorter (mean ‫ע‬ SD, vs.
days; 1 df; ) in the subgroup of patients 29 ‫ע‬ 4 ‫ע46‬ 6 P ! .001 with mean baseline CD4 + cell counts !150 cells/mL. This finding may be a reflection of the intense homeostatic pressure exerted on patients with severe CD4 + cell depletion.
DISCUSSION
Our findings, together with recent data from Mozambique [39] , suggest that treatment of HIV-1 subtype C infections will have significant virological and immunological benefit, even in the context of OIs and low CD4 + cell counts [40, 41] . The ability to successfully treat HIV-1 in Africa is an urgent priority that has far-reaching social and public health implications, in terms of increased life expectancy and productivity, reduced HIV-1 transmission rates, fewer orphaned children, and increased economic stability.
The short-term success rate of our study, as shown by the precipitous phase I decline in plasma viremia and as measured by the proportions of patients reaching undetectable HIV-1 RNA levels by month 3 (93.8% of patients with TB and 80.0% of patients with KS), is equivalent to or better than that reported in many studies of HIV-1 subtype B. In a recent study conducted in Germany, only 64% of patients treated with zidovudine, 3TC, and EFV had viral loads !50 copies/mL at month 4 [42] . In a study conducted in West Africa, the proportions of Senegalese patients who achieved viral loads !50 copies/mL after 3 and 6 months of therapy with ddI, 3TC, and EFV were 26% and 78%, respectively [22] . The reason for the good response in our study is not known, but it does not appear to be related to drug dosage, since the patients in our study received less efavirenz (600 compared with 800 mg/day). By month 10, the TB cure rate in patients receiving rifampin and 600 mg/day EFV was 89%. One notable difference was that the patients with TB in our study received their treatment through a directly observed therapy (DOT) program, and, therefore, adherence to medication was assured. Patients with KS were carefully monitored by use of pill counts and self-reporting. Further studies are needed to determine whether the good responses in our study are due to adherence or to differences in the turnover and size of the phase I compartment in patients with OIs. Mathematical modeling has suggested that the rate and slope of the phase I decline is related not only to the efficacy of treatment but also to the number of productively infected CD4 + T cells and their pretreatment replication potential [25, 28] . Rapid, initial clearance of HIV-1 from the phase I com-partment is highly desirable, since it minimizes do novo infection of newly activated cell populations. This may be particularly important in the context of KS and other chronic conditions, in which new target cells are continually being activated and seeded by ongoing replication.
Our study also underscores the extensive interpatient variability among HIV-1-infected patients with OIs. This heterogeneity, together with the lack of any clear-cut correlations between baseline parameters, suggests a complex interaction between HIV-1 replication, antigen-driven immune activation (either HIV-1 or OI driven), and CD4 + cell depletion. Of particular interest was the lack of a relationship between baseline viral load and CD4 + cell count. + cell counts at the time of enrollment [23, 24] . At the other end of the spectrum, 4.8% of patients with TB and 10.2% of patients with KS had substantial CD4 + cell depletion in the absence of high-level viremia (i.e., !10,000 HIV-1 RNA copies/mL plasma). The reason for the excessive destruction of CD4 + cells in these patients is not known, but it may be related to enhanced turnover of uninfected CD4 + bystander cells [43, 44] . Several studies have shown that the depletion and turnover of infected (and uninfected) T cells is greatly increased in patients with severe disease and that this process is directly linked to immune activation but only indirectly linked to viral load [45] . Although unproven, the increased steepness and depth of the phase I decline in the TB cohort compared with that in the KS cohort suggests that, at the beginning of ART, patients with TB had a larger, or more dynamic, pool of short-lived HIV-1-infected CD4 + cells. Conversely, the more shallow phase I decline followed by a slower, more protracted phase II decline in the KS cohort suggests that these patients had a larger phase II compartment.
Whether the primary agent(s) driving immune activation is HIV-1 alone or a combination of HIV-1 and OI remains to be established [46] [47] [48] [49] [50] . It is reasonable to expect that different pathogens would produce different activation stimuli and that these stimuli would have diverse effects on the size and kinetics of viral clearance from phase I and II reservoirs. Irrespective of the reason, it is becoming increasingly recognized that an improved understanding of phase II virus and its responsiveness to ART will be critical to the eradication of HIV-1 [51] [52] [53] [54] [55] . By using high-resolution therapeutic monitoring, it is now possible to begin deciphering the complex interplay between HIV-1 and OIs. When combined with new tools that measure viral replication in specific cell types [56] [57] [58] [59] and with mathematical modeling of immune activation and target cell availability [25] [26] [27] [28] [29] [30] [31] [32] , this approach will provide a powerful tool for unraveling the impact of OIs on HIV-1 disease. An understanding of these processes is likely to be critical to the optimization of treatment strategies in southern Africa, a region where OIs may play a major role not only in the pathogenesis of HIV-1 disease but also in patient response to therapy. OIs are a major problem for patients failing therapy, and this problem is likely to increase as resistance to antiretroviral drugs becomes more widespread. This study serves to stimulate debate on the role of OI-induced immune activation as a factor contributing to the severity of the AIDS epidemic in Africa and to motivate the development of viral load assays that measure intracellular and tissue reservoirs of HIV-1. Such assays have been developed and are currently undergoing intensive evaluation [38, [56] [57] [58] [59] .
